Sensory neuropathies, from symptoms to treatment

Current Opinion in Neurology

Volumn 23, Issue 5, 2010, Pages 502-508

  Botez, Stephan A ^a   Herrmann, David N ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

diagnostic criteria; distal symmetric polyneuropathy; dysimmune sensory neuropathies; intravenous immunoglobulin; sensory neuropathies

Indexed keywords

BOTULINUM TOXIN A; CAPSAICIN; EPALRESTAT; ETANERCEPT; GABAPENTIN; HARKOSERIDE; IMMUNOGLOBULIN; INFLIXIMAB; LEVACECARNINE; THIOCTIC ACID; VASCULOTROPIN;

AMYLOIDOSIS; AUTONOMIC NEUROPATHY; CONFOCAL MICROSCOPY; CORNEAL CONFOCAL MICROSCOPY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISTAL SYMMETRIC POLYNEUROPATHY; DRUG EFFICACY; DYSIMMUNE SENSORY NEUROPATHY; EVOKED RESPONSE; FAMILIAL AMYLOID POLYNEUROPATHY; GENE TRANSFER; GENETIC SCREENING; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYNEUROPATHY; REVIEW; SENSORY NEUROPATHY; SJOEGREN SYNDROME; SKIN BIOPSY; SMALL FIBER SENSORY NEUROPATHY; TRANSCUTANEOUS NERVE STIMULATION;

BIOPSY; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM; PERIPHERAL NERVES; POLYNEUROPATHIES; SENSORY RECEPTOR CELLS;

EID: 77956394000     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32833c7a19     Document Type: Review

References (58)

1. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research - report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64:199-207.
2. England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009; 72:185-192.
3. Holland NR, Crawford TO, Hauer P. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases. Ann Neurol 1998; 44:47-59.
4. Gorson KC, Herrmann DN, Thiagarajan R, et al. Nonlength dependent small fibre neuropathy/ganglionopathy. J Neurol Neurosurg Psychiatry 2008; 79:163-169.
5. Lauria G, Sghirlanzoni A, Lombardi R, Pareyson D. Epidermal nerve fiber density in sensory ganglionopathies: clinical and neurophysiologic correlations. Muscle Nerve 2001; 24:1034-1039.
6. Lauria G, Pareyson D, Sghirlanzoni A. Neurophysiological diagnosis of acquired sensory ganglionopathies. Eur Neurol 2003; 50:146-152.
7. Lauria G, Cornblath DR, Johansson O, et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol 2005; 12:1-12.
8. McArthur JC, Stocks EA, Hauer P, et al. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol 1998; 55:1513-1520.
9. Bakkers M, Merkies IS, Lauria G, et al. Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology 2009; 73:1142-1148.
10. Smith AG, Howard JR, Kroll R, et al. The reliability of skin biopsy with measurement of intraepidermal nerve fiber density. J Neurol Sci 2005; 228:65-69.
11. England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009; 72:177-184.
12. Devigili G, Tugnoli V, Penza P, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008; 131:1912-1925.
13. Botez SA, Herrmann DN. Pitfalls of diagnostic criteria for small fiber neuropathy. Nat Clin Pract Neurol 2008; 4:586-587.
14. Chao CC, Hsieh SC, Tseng MT, et al. Patterns of contact heat evoked potentials (CHEP) in neuropathy with skin denervation: correlation of CHEP amplitude with intraepidermal nerve fiber density. Clin Neurophysiol 2008; 119:653-661.
15. Atherton DD, Facer P, Roberts KM, et al. Use of the novel Contact Heat Evoked Potential Stimulator (CHEPS) for the assessment of small fibre neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts. BMC Neurol 2007; 7:21.
16. Tavakoli M, Marshall A, Pitceathly R, et al. Corneal confocal microscopy: a novel means to detect nerve fibre damage in idiopathic small fibre neuropathy. Exp Neurol 2010; 223:245-250.
17. Tavakoli M, Marshall A, Thompson L, et al. Corneal confocal microscopy: a novel noninvasive means to diagnose neuropathy in patients with Fabry disease. Muscle Nerve 2009; 40:976-984.
18. Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care 2007; 30:2608-2612.
19. Herrmann DN. Noninvasive and minimally invasive detection and monitoring of peripheral neuropathies. Expert Rev Neurother 2008; 8:1807-1816.
20. Camdessanché JP, Jousserand G, Ferraud K, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain 2009; 132:1723-1733.
21. Burns TM, Phillips LH 2nd, Dimberg EL, et al. Novel myelin protein zero mutation (Arg36Trp) in a patient with acute onset painful neuropathy. Neuromuscul Disord 2006; 16:308-310.
22. Sowden JE, Logigian EL, Malik K, Herrmann DN. Genotype-phenotype correlation in a family with late onset CMT and an MPZ lys236del mutation. J Neurol Neurosurg Psychiatry 2005; 76:442-444.
23. BensonMD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36:411-423.
24. Planté-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007; 69:693-698.
25. Fadic R, Russell JA, Vedanarayanan VV, et al. Sensory ataxic neuropathy as the presenting feature of a novel mitochondrial disease. Neurology 1997; 49:239-324.
26. Van Goethem G, Martin JJ, Dermaut B, et al. Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. Neuromuscul Disord 2003; 13:133-142.
27. McHugh JC, Lonergan R, Howley R, et al. Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) in a sibling pair with a homozygous p.A467T POLG mutation. Muscle Nerve 2010; 41:265-269.
28. Milone M, Brunetti-Pierri N, Tang LY, et al. Sensory ataxic neuropathy with ophthalmoparesis caused by POLG mutations. Neuromuscul Disord 2008; 18:626-632.
29. Schulte C, Synofzik M, Gasser T, Schöls L. Ataxia with ophthalmoplegia or sensory neuropathy is frequently caused by POLG mutations. Neurology 2009; 73:898-900.
30. Gorson KC, Ropper AH. Positive salivary gland biopsy, Sjogren;s syndrome, and neuropathy: clinical implications. Muscle Nerve 2003; 28:553-560.
31. Figueroa JJ, Tabechian D, Herrmann DN. Severe long-standing dysimmune sensory neuronopathy responsive to etanercept. J Clin Neuromuscul Dis 2008; 9:415-420.
32. Molina JA, Benito-Leó n J, Bermejo F, et al. Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren;s syndrome. J Neurol Neurosurg Psychiatry 1996; 60:699.
33. Takahashi Y, Takata T, Hoshino M, et al. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren;s syndrome. IV immunoglobulin. Neurology 2003; 60:503-505.
34. Caroyer JM, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjögren;s syndrome. Neurology 2002; 59:1113-1114.
35. Kizawa M, Mori K, Iijima M, et al. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren;s syndrome. J Neurol Neurosurg Psychiatry 2006; 77:967-969.
36. Morozumi S, Kawagashira Y, Iijima M, et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren;s syndrome. J Neurol Sci 2009; 279:57-61.
37. Robinson-Papp J, Simpson DM. Neuromuscular diseases associated with HIV-1 infection. Muscle Nerve 2009; 40:1043-1053.
38. Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004; 61:546-551.
39. Wallace VC, Blackbeard J, Pheby T, et al. Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain 2007; 133:47-63.
40. Youle M, Osio M, ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007; 8:241-250.
41. Valcour V, Yeh TM, Bartt R, et al. Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIVMed 2009; 10:103-110.
42. Hahn K, Arendt G, Braun JS, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004; 251:1260-1266.
43. Simpson DM, Schifitto G, Clifford DB, et al., 1066 HIV Neuropathy Study Group. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 2010; 74:413-420.
44. Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1998; 280:1590-1595.
45. Simpson DM, Brown S, Tobias J, et al. Controlled trial of high concentration capsaicin patch for treatment of painful HIV polyneuropathy. Neurology 2008; 70:2305-2313.
46. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2008; 34:672-680.
47. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during The Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions, and Complications (EDIC) Study. Diabetes Care 2010; 33:1090-1096.
48. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29:2365-2370.
49. Ziegler D, Low PA, Boulton AJM, et al. Effect of 4-year antioxidant treatment with a-lipoic acid in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes 2007; 56 (Suppl. 1):A2.
50. Ziegler D. Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diabetes Care 2009; 32 (Suppl 2):S414-S419.
51. Ropper AH, Gorson KC, Gooch CL, et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol 2009; 65:386-393.
52. Dubinsky RM, Miyasaki J. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidencebased review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74:173-176.
53. Forst T, Nguyen M, Forst S, et al. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device. Diabetes Nutr Metab 2004; 17:163-168.
54. Kumar D, Marshall H. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care 1997; 20:1702-1705.
55. Wymer JP, Simpson J, Sen D, Bongardt S, Lacosamide SP742 Study Group. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain 2009; 25:376-385.
56. Shaibani A, Fares S, Selam JL, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain 2009; 10:818-828.
57. Ziegler D, Hidvé gi T, Gurieva I, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010; 33:839-841.
58. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009; 72:1473-1478.